التفاصيل البيبلوغرافية
| العنوان: |
Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials. |
| المؤلفون: |
Merz, V.1,2 (AUTHOR) valeria.merz@univr.it, Messina, C.3 (AUTHOR), Zecchetto, C.2,4 (AUTHOR), Quinzii, A.2,4 (AUTHOR), Frisinghelli, M.1 (AUTHOR), Trentin, C.1 (AUTHOR), Salati, M.5 (AUTHOR), Caffo, O.1 (AUTHOR), Melisi, D.2,6 (AUTHOR) |
| المصدر: |
Clinical Oncology. Feb2024, Vol. 36 Issue 2, p87-97. 11p. |
| مصطلحات موضوعية: |
*THERAPEUTIC use of antineoplastic agents, *ARTIFICIAL membranes, *ONLINE information services, *MEDICAL databases, *FOLINIC acid, *META-analysis, *MEDICAL information storage & retrieval systems, *CONFIDENCE intervals, *IRINOTECAN, *TREATMENT effectiveness, *CANCER patients, *TUMOR classification, *DESCRIPTIVE statistics, *MEDLINE, *OXALIPLATIN, *PROGRESSION-free survival, *ODDS ratio, *OVERALL survival, BILE duct tumors |
| مستخلص: |
The combination of 5-fluorouracil/leucovorin (5-FU/LV) plus oxaliplatin (FOLFOX) is widely acknowledged as the standard regimen for second-line treatment in patients with advanced biliary tract cancer. Nanoliposomal irinotecan (nal-IRI) has demonstrated its activity in patients with advanced pancreatic cancer. Recent studies have investigated the activity of nal-IRI in combination with 5-FU/LV for biliary tract cancer. However, the results have been contradictory. We conducted a meta-analysis to assess survival outcomes and response rates in randomised trials investigating the activity of nal-IRI in previously treated biliary tract cancer patients. We systematically collected potentially relevant findings from PubMed/Medline, the Cochrane library and EMBASE. Abstracts presented at major international oncological meetings were also reviewed. We extracted hazard ratios and 95% confidence intervals for progression-free survival and overall survival, as well as odds ratios and 95% confidence intervals for objective response rate. The outcomes of the accessible randomised studies evaluating the activity of nal-IRI plus 5-FU/LV were analysed. The combination therapy exhibited a statistically significant decrease in the risk of progression (hazard ratio 0.70; 95% confidence interval 0.50–0.97) when compared with 5-FU/LV alone. Additionally, the dual regimen yielded longer overall survival and a higher objective response rate. Our meta-analysis showed that nal-IRI plus 5-FU/LV had a superior activity in comparison with 5-FU/LV. Further investigations are required to elucidate the role of nal-IRI in this setting and to identify subgroups of patients who could derive the greatest benefit from its administration. • No evidence that doublet therapy is more effective than monotherapy in second-line treatment of biliary tract cancer. • FOLFOX demonstrated higher activity compared with active symptom control. • Two studies showed conflicting results assessing the activity of 5-FU/LV ± nal-IRI. • Our meta-analysis supports the role of nal-IRI in biliary tract cancer. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
